Tumor Necrosis Factor-alpha clinical trials at UCSF

1 research study open to eligible people

Tumor necrosis factor-alpha is a protein involved in inflammation in the body. UCSF is conducting research on how infliximab may help people with a specific type of brain aneurysm that can lead to serious complications. These complications include strokes and pressure on the brainstem.

Showing trials for

  • Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

    open to eligible people ages 18 years and up

    Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

    San Francisco, California

Our lead scientists for Tumor Necrosis Factor-alpha research studies include .

Last updated: